-
The first CAR-T product independently developed in China and approved as a Category 1 biologics product, and the sixth approved CAR-T product globally
-
Currently the only approved CAR-T product that has been simultaneously included in the National Significant New Drug Development Program, granted priority review and breakthrough therapy designation
-
May provide a best-in-class CAR-T therapy in China given its demonstration of high rates of durable disease response and low rates of CAR-T associated toxicities
Cord Blood Bank Cryoviva Singapore Continues Geographic Expansion with Entry into Bahrian
Singapore, Sep 7, 2021 – Local family cord blood bank Cryoviva Singapore is continuing with its rapid geographic growth plans with an entry into the Bahrain market. This latest new market entry closely follows Cryoviva establishing a footprint in Dubai to serve couples in the UAE that are on the family way. [Read more…]
Treefrog Therapeutics Secures $75M in Series B Financing To Advance a Pipeline of Stem Cell-Derived Cell Therapies and Deploy Proprietary C-Stem™ Technology in the USA & Japan
Frederic Desdouits, PhD, named chief executive officer. Co-founder Kevin Alessandri, PhD, relocates to Boston to drive TreeFrog Therapeutics’ expansion in the U.S.
Bordeaux, France/September 13th, 2021 – TreeFrog Therapeutics, a privately held French-based biotech startup focused on developing safe and affordable stem cell-derived cell therapies for millions of patients, today announced the successful closing of a $75 million (€64M) Series B financing round, bringing the total funding to date to $83 million (€70M). [Read more…]
Hemostemix. The Canadian Biotech that Could Change Healthcare as We Know It.
Hemostemix Inc. (“Hemostemix”) (TSX Venture:HEM; OTCQB:HMTXF) is a publicly traded clinical-stage biotech company that develops and commercializes blood-derived stem cell therapies for medical conditions lacking adequate treatment options. Importantly, it is one of the first clinical-stage biotech companies to test a stem cell therapy within an international, multi-center Phase II clinical trial for patients with critical limb ischemia (“CLI”). CLI is a severe form of peripheral artery disease (“PAD”) that is caused by reduced blood flow to the extremities. [Read more…]
I Peace expands its clinical-grade iPSC banking service leveraging mass manufacturing capability
September 7, 2021, Palo Alto, California – I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech startup focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) expands its personalized iPSC banking service. I Peace launched its clinical-grade personalized iPSC banking service in 2020 in Japan and has already banked several individuals’ iPSCs. The company will collaborate with I’rom Group Co., Ltd. (Japan) to make the service available for clients at every corner of the country. Using this as proof of concept, I Peace plans to launch the iPSC banking service in the U.S. as the next phase of its business expansion. [Read more…]
- « Previous Page
- 1
- …
- 154
- 155
- 156
- 157
- 158
- …
- 334
- Next Page »